PharmAla Biotech Holdings Inc. (MDXXF)
OTC PINK 
Summary
PharmAla Biotech Holdings Inc. (MDXXF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PharmAla Biotech Holdings Inc. ever had a stock split?
PharmAla Biotech Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | OTC PINK Exchange | CA71719L1067 ISIN |
| United States Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Pharmala Biotech Holdings Inc., which operates under the name PharmAla, is a company committed to the development, manufacturing, and commercialization of a specific class of drugs known as substituted methylenedioxy-phenethylamines (MDXX). This niche focus positions PharmAla as a pioneer in its field, aiming to offer novel active pharmaceutical ingredients (APIs) within this chemical class. Located in Vancouver, Canada, the company stands out for its dedication to advancing the research and accessibility of MDXX compounds, potentially reshaping therapeutic approaches in various medical contexts.
Products and Services
- 1,3-Benzodioxolyl-N-methylbutanamine (MBDB)
- 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE)
- Formulations of MDXX compounds
This compound is one of the company's flagship products. MBDB forms part of the MDXX class, known for its psychoactive properties which have been explored for potential therapeutic uses. PharmAla's investment in the development and manufacturing of MBDB showcases their commitment to exploring the less-known territories of MDXX compounds for possible medical applications.
MDEA, also known as MDE, is another critical component of PharmAla's product lineup. This substance shares the core structural characteristics of the MDXX class, offering unique properties that hold interest for therapeutic purposes. The company's work with MDEA underpins its broader goal to diversify and deepen the understanding of MDXX compounds and their potential benefits.
In addition to providing individual MDXX class compounds, PharmAla also specializes in the formulation of these substances. This service not only demonstrates the company’s comprehensive capabilities in drug development but also enhances the accessibility and applicability of MDXX compounds across various therapeutic areas. The ability to formulate these compounds allows for more targeted research and potential treatment options, solidifying PharmAla's role in the progression of MDXX-based therapy.
